Johnson & Johnson's HIV vaccine candidate has failed its first major efficacy test, as it was unable to protect women against infection with the virus in a phase 2b trial carried out in sub ...

The first human clinical trials testing a new strategy to protect against HIV infections have yielded promising early results ...

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine ...

Anti-HIV mRNA vaccines are already in development, some in early-stage human trials. There is no evidence that mRNA vaccines can alter human DNA. Yes, an mRNA vaccine might well work against HIV, and ...

Worldwide, an estimated 40 million people live with HIV. Two-thirds of this group are on the African continent. In 2023, more ...